Physician profile
Samuel B Wolf
NPI 1215905989
$5,609.09
in general payments reported to CMS, 2019-2025
32 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $424 · 2021: $780 · 2022: $618 · 2023: $2,757 · 2024: $182 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Travel and Lodging: $1,354 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.72 |
| Travel and Lodging | $1,353.68 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,888.22 | 2023 | |
| Boston Scientific Corporation | $1,153.90 | 2019-2025 | Solyx Sis System |
| Astellas Pharma US INC | $515.54 | 2019-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $361.73 | 2020-2021 | |
| Roche Diagnostics Corporation | $361.72 | 2019-2020 | |
| Abbvie INC. | $271.97 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Pfizer INC. | $190.69 | 2019-2023 | |
| Coloplast Corp | $150.59 | 2019-2023 | Altis |
| Bayer Healthcare Pharmaceuticals INC. | $136.84 | 2019-2025 | |
| Coopersurgical, INC. | $98.01 | 2022-2023 | Summit Doppler, Mara Console |
| Duchesnay USA Incorporated | $54.82 | 2019 | |
| Mayne Pharma Commercial LLC | $54.01 | 2022-2023 | |
| Organon LLC | $49.57 | 2021-2023 | Nexplanon |
| Sage Therapeutics, LLC | $39.83 | 2024 | |
| Sumitomo Pharma America, INC. | $32.87 | 2023 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $32.13 | 2023-2025 | Slynd |
| Hologic Sales and Service, LLC | $27.94 | 2021 | |
| Intuitive Surgical, INC. | $27.46 | 2025 | |
| Merck Sharp & Dohme LLC | $25.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $23.10 | 2021 | |
| Ethicon US, LLC | $21.13 | 2019 | |
| Axonics, INC. | $19.81 | 2020 | |
| Channel Medsystems, INC. | $17.08 | 2024 | |
| Medtronic, INC. | $16.34 | 2025 | Ligasure |
| Myovant Sciences INC. | $14.29 | 2021 | |
| Therapeuticsmd, INC. | $12.28 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.41 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.